Nina Moker

Bergisch Gladbach, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Journal: Frontiers in immunology
Published: December 05, 2025

Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.

Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.

Journal: Immunology and cell biology
Published: August 15, 2025

Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.

Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.

Journal: Frontiers in immunology
Published: December 19, 2024

Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.

Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.

Journal: Immunology and cell biology
Published: November 04, 2024

Impact of IL-21 on Natural Killer cell proliferation and function - a mathematical and functional assessment.

Impact of IL-21 on Natural Killer cell proliferation and function - a mathematical and functional assessment.

Journal: bioRxiv : the preprint server for biology
Published: February 14, 2024

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression.

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression.

Journal: Nature immunology
Published: January 19, 2024

Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.

Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.

Journal: Bone marrow transplantation
Published: August 04, 2023

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

Journal: Nature communications
Published: January 17, 2023

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 14, 2021

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.

Journal: Frontiers in immunology
Published: October 19, 2021

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Journal: Frontiers in immunology
Published: November 07, 2019

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Journal: Frontiers in immunology
Published: May 08, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026